“Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40 ” was registered on the International Cosmetics Ingredient Dictionary in December 2014. This can be found on page 2096 of the ICID 2016 Vol.2. The INCI name “Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40” is not defined by the applicant company. This is the name assigned by the PCPC who organizes ICID in Washington and global cosmetic companies for classification of the ingredient. ‘Clostridium Botulinum’ designation on INCI name proves that the material actually derived from ‘Botulinum To xin ‘.
However, the name ‘Clostridium Botulinum’ is not only important. Botulinum to xin light chain’ alone can not can not penetrate nerve cells even it penetrated in to the skin, so it can not be effective. The core technology of MTD which realizes infiltration into the skin and infiltration of nerve cells has been applied, and botulinum-derived ingredient that we have dreamed of has been born. The ingredient has name ‘Clostridium Botulinum’ can be developed but the technology and efficacy can not be imitated.
Novel cell penetrating peptide, conjugate thereof with botulinum tox in, and use thereof Patent pending technology patent of ” Methionyl r-Clostridium Botulinum Polypeptide-1 Hexapeptide-40 ” is currently being filed in eight major countries in the world. This technology patent was developed through joint research between ATGC Co., Ltd., which possesses botulinum tox in technology, and Procel Therapeutics Co., Ltd., which possesses skin and target cell penetration technology.
BPMed Cosmetic Co., Ltd. owns the exclusive right to use the patent and the exclusive right to use the material.
- Completed patent registration in Korea (KR.10-1882461)
- Completed patent registration in Japan (JP.6243577)
- Completed patent registration in Russia (RUS.2670135)